Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy
Pohl, A, El-Khoueiry, A, Yang, D, Zhang, W, Lurje, G, Ning, Y, Winder, T, Hu-Lieskoven, S, Iqbal, S, Danenberg, K D, Kahn, M, Teo, J-L, Shriki, J, Stebbing, J, Lenz, H-JLanguage:
english
Pages:
11
Journal:
The Pharmacogenomics Journal
DOI:
10.1038/tpj.2011.61
Date:
January, 2012
File:
PDF, 401 KB
english, 2012
File converter
More search results
More benefits 
